Furthermore, our results highlight the clinical potential of CXCR4-targeting nanobody constructs to direct NK cells to CLL cells, and demonstrate that autologous NK cells can be employed for immunotherapeutic strategies in CLL. This evidence concerns the gene CXCR4 and B-cell chronic lymphocytic leukemia.